StockUS listing USTYPTFPINKHealthcareCapital Destroyer

Entropy Neurodynamics Limited(TYPTF) Stock Analysis | Healthcare

USD --+0.00%
Reward29Low
Risk29Low
75%Data
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 20.11M
Reward Ratingⓘ29 Low reward assessment · 75% data coverage
Bottom 1% of stocksView factors
Risk Ratingⓘ29 Low risk assessment · 75% data coverage
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on TYPTF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Entropy Neurodynamics Limited?

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States.

AI Brief Pro

The brief on Entropy Neurodynamics Limited

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Entropy Neurodynamics Limited?

Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 20.11M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (29)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
BetaN/A
Insider Activity
12M windowNo data
No insider activity data available for this ticker.